首页> 外文期刊>The journal of immunology >A Critical Role for P2X7 Receptor–Induced VCAM-1 Shedding and Neutrophil Infiltration during Acute Lung Injury
【24h】

A Critical Role for P2X7 Receptor–Induced VCAM-1 Shedding and Neutrophil Infiltration during Acute Lung Injury

机译:在急性肺损伤中P2X7受体诱导的VCAM-1脱落和中性粒细胞浸润的关键作用。

获取原文
           

摘要

Pulmonary neutrophils are the initial inflammatory cells that are recruited during lung injury and are crucial for innate immunity. However, pathological recruitment of neutrophils results in lung injury. The objective of this study is to determine whether the novel neutrophil chemoattractant, soluble VCAM-1 (sVCAM-1), recruits pathological levels of neutrophils to injury sites and amplifies lung inflammation during acute lung injury. The mice with P2X7 receptor deficiency, or treated with a P2X7 receptor inhibitor or anti–VCAM-1 Abs, were subjected to a clinically relevant two-hit LPS and mechanical ventilation–induced acute lung injury. Neutrophil infiltration and lung inflammation were measured. Neutrophil chemotactic activities were determined by a chemotaxis assay. VCAM-1 shedding and signaling pathways were assessed in isolated lung epithelial cells. Ab neutralization of sVCAM-1 or deficiency or antagonism of P2X7R reduced neutrophil infiltration and proinflammatory cytokine levels. The ligands for sVCAM-1 were increased during acute lung injury. sVCAM-1 had neutrophil chemotactic activities and activated alveolar macrophages. VCAM-1 is released into the alveolar airspace from alveolar epithelial type I cells through P2X7 receptor–mediated activation of the metalloproteinase ADAM-17. In conclusion, sVCAM-1 is a novel chemoattractant for neutrophils and an activator for alveolar macrophages. Targeting sVCAM-1 provides a therapeutic intervention that could block pathological neutrophil recruitment, without interfering with the physiological recruitment of neutrophils, thus avoiding the impairment of host defenses.
机译:肺中性粒细胞是在肺损伤期间募集的初始炎症细胞,对于先天免疫至关重要。然而,嗜中性粒细胞的病理募集导致肺损伤。这项研究的目的是确定新型中性粒细胞趋化剂可溶性VCAM-1(sVCAM-1)是否将中性粒细胞的病理学水平募集到损伤部位,并在急性肺损伤期间扩大肺部炎症。患有P2X7受体缺乏症或经P2X7受体抑制剂或抗VCAM-1 Abs治疗的小鼠遭受了临床相关的两次打击LPS和机械通气引起的急性肺损伤。测量中性粒细胞浸润和肺部炎症。中性粒细胞的趋化活性通过趋化性测定来确定。在分离的肺上皮细胞中评估了VCAM-1脱落和信号传导途径。 sVCAM-1的中和或P2X7R缺乏或拮抗可减少中性粒细胞浸润和促炎细胞因子水平。在急性肺损伤期间,sVCAM-1的配体增加。 sVCAM-1具有中性粒细胞趋化活性和活化的肺泡巨噬细胞。 VCAM-1通过P2X7受体介导的金属蛋白酶ADAM-17的活化从I型肺泡上皮细胞释放到肺泡空域。总之,sVCAM-1是嗜中性粒细胞的新型化学引诱剂,也是肺泡巨噬细胞的激活剂。靶向sVCAM-1提供了一种治疗性干预措施,可以阻止病理性中性粒细胞的募集,而不会干扰中性粒细胞的生理募集,从而避免了宿主防御能力的损害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号